menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Investigating Plinabulin as Immune-Modifying Therapy for Non-Small Cell Lung Cancer (NSCLC)

Each year more people die of lung cancer than of colon, breast, and prostate cancers combined.  Non-small cell lung cancer, which accounts for 85% ...
  • Sponsored by

  • Overview

    Each year more people die of lung cancer than of colon, breast, and prostate cancers combined.  Non-small cell lung cancer, which accounts for 85% of lung cancer cases, has been the key target of several clinical trials evaluating new immune-modifying agents. 

    Dr. Alan Mita, Associate Professor of Medicine and Co-Director of Experimental Therapeutics at the Samuel Oschin Comprehensive Cancer Institute of Cedar Sinai Medical Center in Los Angeles joins host, Dr. Matt Birnholz, to discuss one such drug therapy entering this immune oncology space and ways for oncologists treating patients with non-small cell lung cancer to get involved in this drug’s global phase 3 trial directly.  

    To inquire about participating in the trial please contact BeyondSpring Pharmaceuticals at general@beyondspringpharma.com.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.